Additionally, acetate supplementation significantly mitigated NEC-induced goblet cell loss and increased MUC2 expression, effects that were blocked by GLPG0974 treatment or GPR41 knockout (Figures 6a,b). This evidence concerns the gene FFAR3 and necrotizing enterocolitis.